Shopping Cart
Remove All
Your shopping cart is currently empty
Kif15-IN-2 is a kinesin Kif15 inhibitor with potential anticancer activity and can be used in prostate cancer research.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 2 mg | $399 | - | In Stock |
| Description | Kif15-IN-2 is a kinesin Kif15 inhibitor with potential anticancer activity and can be used in prostate cancer research. |
| In vitro | Kif15-IN-2 (Compound 14) is an inhibitor targeting the mitotic kinase Hs Kif15, with potential activity against proliferative diseases such as cancer, hyperplasia, restenosis, cardiac hypertrophy, immunological disorders, and inflammation[1]. |
| Molecular Weight | 440.48 |
| Formula | C20H20N6O4S |
| Cas No. | 672926-33-9 |
| Smiles | CC(C)[C@@H](C(=O)Nc1nc(C)c(s1)-c1nnc(C)o1)n1c(=O)[nH]c2ccccc2c1=O |
| Relative Density. | 1.409 g/cm3 (Predicted) |
| Color | White |
| Appearance | Solid |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||
| Solubility Information | DMSO: 15 mg/mL (34.05 mM), Sonication is recommended. | |||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.54 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.